Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France
Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted quadrivalent influenza vaccine (aQIV) compared to standard (SD-QIV) and high-dose (HD-QIV) quadrivalent influenza v...
Alternative Titles
Full title
Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_131cc94a7cc44a68a7a4edf1e30dea29
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_131cc94a7cc44a68a7a4edf1e30dea29
Other Identifiers
ISSN
2076-393X
E-ISSN
2076-393X
DOI
10.3390/vaccines12060574
